Senior Vice President, Pricing & Market Access
Douglas leads EVERSANA’s pricing and market access team to strategically drive new drugs to the global market. A proven European Market Access launch readiness and commmercialisation expert with 15 years in healthcare, health economics and the pharmaceutical industry, Douglas has extensive experience across a range of therapeutic areas, including neurology, infectious diseases, nephrology, vaccines and rare diseases. Prior to joining EVERSANA, Douglas held leadership roles in established and emerging pharmaceutical organizations and recently was Head of Market Access EU and Rest-of-World for Santhera Pharmaceuticals where he prepared the European launch for the Duchenne muscular dystrophy portfolio. Prior, he led European market access strategies for neuroscience products at Lupin and worked for Vifor, Cubist, Novartis Vaccines and Abbvie/Abbott. Throughout his career, he has led market access and pricing activities for drug launches at the global and local levels.
Douglas is an active member of the International Society of Pharmacoeconomics and Outcome Research, International Health Economic Association, and Deutsche Gesellschaft für Gesundheitsökonomie (The German Health Economic Association). He holds a master’s degree in economics from University Heidelberg, Germany.